Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02132598 · ClinicalTrials.gov registry record · Phase 2
Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
A Phase 2 study, sponsored by Liza Villaruz, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02132598 is a Phase 2 study that was terminated before completion, run by Liza Villaruz, MD. The registered enrollment target is 5 participants.
The verdict
NCT02132598, a Phase 2 study, was terminated before completion, sponsored by Liza Villaruz, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an open-label phase II clinical trial designed to allow a preliminary assessment of the efficacy and safety of cabozantinib in unselected Non-Small Cell Lung Cancer (NSCLC) patients with metastases to the brain and in the subset of patients with c-MET amplified Non-Small Cell Lung Cancer with metastases to the brain. Previously treated patients with non-squamous NSCLC who have had brain metastases at any point in their treatment history are eligible for enrollment on this clinical trial. Patients with clinically asymptomatic untreated brain metastases will be allowed on trial at the discretion of the treating investigator. Patients who have undergone treatment for their brain metastases with Whole-Brain Radiation Therapy (WBRT), stereotactic radiosurgery (SRS) or surgery must be clinically stable and recovered from all procedures at the time of study enrollment.
Interventions
- DRUG cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-12 |
| Est. Completion | 2019-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02132598
The ClinicalTrials.gov registry entry for NCT02132598 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Liza Villaruz, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cabozantinib is the first listed.
NCT02132598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02132598 about?
NCT02132598 is a clinical study titled "Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases". This is an open-label phase II clinical trial designed to allow a preliminary assessment of the efficacy and safety of cabozantinib in unselected Non-Small Cell Lung Cancer (NSCLC) patients with metastases to the brain and in the subset of patients with c-MET amplified Non-Small Cell Lung Cancer wit...
What is the current status of trial NCT02132598?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2015-12. Estimated completion is 2019-08-09.
What interventions are being tested in trial NCT02132598?
The interventions under investigation include: cabozantinib (DRUG).
Who is sponsoring clinical trial NCT02132598?
This trial is sponsored by Liza Villaruz, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.